Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

Cabozantinib (XL-184) is a multitarget tyrosine kinase inhibitor (TKI) targeting receptor tyrosine kinases (RTKs) involved in oncogenesis and angiogenesis. It is currently the standard therapy for medullary thyroid cancer (MTC), metastatic renal cell carcinoma (mRCC), and hepatocellular carcinoma (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Scirocchi, Fabio, Napoletano, Chiara, Pace, Angelica, Rahimi Koshkaki, Hassan, Di Filippo, Alessandra, Zizzari, Ilaria Grazia, Nuti, Marianna, Rughetti, Aurelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564482/
https://www.ncbi.nlm.nih.gov/pubmed/34745989
http://dx.doi.org/10.3389/fonc.2021.755433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564482/
https://www.ncbi.nlm.nih.gov/pubmed/34745989
http://dx.doi.org/10.3389/fonc.2021.755433

Ejemplares similares